| Abstract | Objectives: The aim of this study is to determine urotensin-II (U-II) levels in obese children and adolescents with metabolic syndrome (MS) compared to obese children and adolescents without MS.
Patients and methods: This study enrolled 20 obese children and adolescents with MS and 20 obese children and adolescents without MS. Evaluation included physical examination, medical history, anthropometric measurement, blood pressure measurement and blood sample. IDF guidelines was used for MS criteria. Serum U-II levels were determined with enzyme-linked immunosorbent assay kit.
Results: Subjects with MS has significantly higher serum levels of U-II compared to the subjects without MS (9.23 ± 9.69 vs 3.81 ± 1.94). Additionally, we found that obese subjects with high blood pressure had higher serum U-II when compared with obese children and adolescents with normal blood pressure (8.59 ± 9.13 vs 3.68 ± 2.06, P = 0.027).
Conclusion: Serum U-II levels is significantly increased in obese children and adolescents with MS compared to children and without MS which implies possible involvement of U-II in MS pathophysiology. To address these findings, larger multicentric investigations are needed in the future. |
| Abstract (croatian) | Ciljevi: Cilj ovog istraživanja je bilo odrediti razinu urotenzina-II (U-II) u pretile djece i adolescencije s metaboličkim sindromom (MS) u usporedbi s pretilom djecom i adolescenciji bez MS-a.
Materijali i metode: Ovo je istraživanje obuhvatilo 20 pretile djece i adolescencije s MS-om i 20 pretile djece i adolescencije bez MS-a. Evaluacija je obuhvaćala fizikalni pregled, anamnezu, antropometrijsko mjerenje, mjerenje krvnog tlaka i uzorkovanje krvi. MS je definiram prema IDF definiciji. Razine U-II u serumu određene su enzim- imunoadsorpcijskom metodom.
Rezultati: Ispitanici s MS imali su statistički značajno višu razinu U-II u serumu u usporedbi s ispitanicima bez MS (9,23 ± 9,69 vs 3,81 ± 1,94, P = 0,035). Također, pokazali smo da su pretili ispitanici s visokim krvnim tlakom imali statistički značajno više serumske razine U-II u usporedbi s pretilom djecom i adolescentima s normalnim krvnim tlakom (8,59 ± 9,13 vs 3,68 ± 2,06, P = 0,027).
Zaključci: Razina U-II u serumu značajno je povećana u pretile djece i adolescencije s MS-om u usporedbi s djecom i adolescenciji bez MS-a, što implicira moguće sudjelovanje U-II u patofiziologiji MS-a. Potrebna su veća multicentrična istraživanja kako bih se razjasnila uloga U-II. |
